LearnGlossaryMarketStocksSuperinvestorsSign in

KOD

Kodiak Sciences Inc.

Healthcare · $5.6B market cap

Verdict

We can't put a fair value on KOD right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-30.9% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-64.7%✗

Follow KOD

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds KOD. In Q2 2026, 1 trimmed. Who we track

Polen Capital Management

Polen Capital Management · as of Q2 2026

$1.4M

35,469 shares

Moves in Q2 2026

Trimmed: Polen Capital Management

About Kodiak Sciences Inc.

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works